Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Must have been taking a stable dose of basal or premixed insulin for 8 weeks or longer prior to screening~* If taking metformin, must have been taking the same daily dose for 8 weeks or longer prior to screening~* Insulin type should be intermediate- or long-acting (basal) or premixed (premixed formulation may include short- or rapid-acting insulin as 1 component).~* Inadequate glycemic control (A1C of 7.5% to 11.0%, inclusive)~* Body mass index of 45 kg/m² or lower~* Fasting C-peptide level of 0.8 ng/mL or higher~Exclusion Criteria:~* Symptoms of poorly controlled diabetes, including but not limited to marked polyuria and polydipsia with greater than 10% weight loss during the last 3 months prior to screening or other signs and symptoms~* History of diabetic ketoacidosis or hyperosmolar nonketotic coma~* Women of childbearing potential unable or unwilling to use acceptable birth control~* Women who are pregnant or breastfeeding~* Active liver disease~* Anemia~* Chronic or repeated intermittent corticosteroid treatment (participants receiving stable doses of replacement corticosteroid (except dexamethasone) therapy may be enrolled)~* Use of short- or rapid-acting insulin~* Significant cardiovascular history defined as: myocardial infarction, coronary angioplasty or bypass graft, valvular disease or repair, unstable angina pectoris, transient ischemic attack, or cerebrovascular accident~* Congestive heart failure~* Unstable or rapidly progressing renal disease~* History of alcohol or drug abuse within the previous year~* History of hemoglobinopathies~* Unstable major psychiatric disorders~* Immunocompromised status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin, 5 mg + insulin (Type: EXPERIMENTAL): Saxagliptin, 5 mg, plus insulin, administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
- Placebo + insulin (Type: PLACEBO_COMPARATOR): Placebo administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).